.Creating value through therapeutic innovation
About NicOx Products Maximizing portfolio People Investor & media
Profile
Pipeline		 Naproxcinod
NCX 6560
 Full portfolio		 Co-development
Alliances
Technology		 Board of Directors
Management Team
Contacts
Careers		 Press releases
 Investor relations
Fact file
Financials
Corporate governance

Company Report 2006


Financial Report 2006


 
News......

NicOx to present at financial conferences in New York and London on June 25

May 28, 2008NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study
May 27, 2008NicOx announces departure of Damian Marron for CEO position
May 14, 2008NicOx reports first quarter 2008 financial results.
May 13, 2008NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc.
May 6, 2008NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
March 19, 2008NicOx signs agreement for the commercial manufacture of naproxcinod drug substance

NicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs for unmet medical needs.
NicOx is targeting the therapeutic areas of inflammatory and cardiometabolic diseases.
NicOx aims to build itself into a self-sustaining, fully integrated bio-pharmaceutical company.
Scientific publications Conferences Directions to NicOx Legal notice Site en français